PAVmed Files to Sell 9.23M Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy PAVM?
PAVmed files to sell 9.23M shares of common stock for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAVM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAVM
Wall Street analysts forecast PAVM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.450
Low
17.00
Averages
17.00
High
17.00
Current: 6.450
Low
17.00
Averages
17.00
High
17.00
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PAVmed Set to Announce Q1 Earnings on May 15
- Earnings Announcement Date: PAVmed (PAVM) is scheduled to announce its Q1 earnings on May 15 after market close, with a consensus EPS estimate of -$0.69, reflecting a staggering 885.7% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations Decline: The anticipated revenue for Q1 is $0.07 million, representing a 12.5% year-over-year decrease, which highlights the company's struggles in revenue growth and may impact investor confidence and future financing capabilities.
- Historical Performance Review: Over the past two years, PAVmed has beaten EPS estimates 63% of the time and revenue estimates 50% of the time; however, the current expectations indicate a notable downturn, potentially affecting market perceptions of its future performance.
- Estimate Revision Status: In the last three months, there has been one upward revision and no downward revisions to EPS estimates, suggesting fluctuations in analyst confidence regarding the company's future performance, which may reflect broader concerns about its profitability.
See More
PAVmed Q1 2026 Earnings Call Insights
- Capital Structure Optimization: PAVmed has completed its restructuring, resulting in a clean capital structure consisting solely of common stock and term debt, which positions the company well to execute its high-growth, diversified life sciences mission.
- Medical Device Portfolio Relaunch: Under the leadership of Joe Virgilio, PAVmed is relaunching its medical device portfolio, including PortIO and endoscopic imaging technology licensed from Duke University, which is expected to drive the introduction of commercial assets and enhance market competitiveness.
- Improved Financial Position: As of March 31, PAVmed reported cash of $6.5 million, with an anticipated $30 million from warrant exercises, which will further bolster the company's liquidity and investment capacity.
- Profitability Challenges: Despite a GAAP net loss of $1.1 million in Q1, the adjusted loss per share was only $0.04 after excluding preferred dividends, indicating the company's efforts in cost control and operational optimization.
See More
PAVmed Q1 Earnings Miss Expectations
- Disappointing Earnings: PAVmed reported a Q1 non-GAAP EPS of -$1.17, missing expectations by $0.48, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company's revenue for Q1 was only $0.02 million, a sharp drop from $8,000 year-over-year, failing to meet the expected $0.08 million, reflecting weak market demand and insufficient sales strategies.
- Improved Cash Position: As of March 31, 2026, PAVmed had cash and cash equivalents of $6.5 million, a significant increase from $1.5 million as of December 31, 2025, indicating better cash management that may support future operations.
- Uncertain Future Outlook: Despite the improved cash position, ongoing losses and declining revenue may raise investor concerns about the company's growth potential, impacting its market performance and ability to secure financing.
See More
PAVmed Reports Business Expansion and Financial Update
- Financial Structure Optimization: PAVmed has simplified its capital structure and strengthened its balance sheet, enabling the company to focus on executing its core businesses and evaluate asset acquisition opportunities aligned with its long-term growth strategy, thereby laying a foundation for future expansion.
- Veris Health Progress: Veris Health continues to expand its commercial engagement with OSU-The James while advancing the FDA submission process for its implantable physiological monitor, which will enhance the company's market position in personalized cancer care.
- Lucid Diagnostics Momentum: Lucid Diagnostics has made significant progress in the commercialization of EsoGuard and strengthened its balance sheet ahead of upcoming Medicare coverage, which will support the company's future revenue growth.
- Medical Device Portfolio Relaunch: Under Joseph Virgilio's leadership, PAVmed is actively advancing its relaunched medical device portfolio while evaluating additional acquisition opportunities to enhance its market competitiveness and drive technological innovation.
See More
PAVmed to Host Business Update Conference Call
- Conference Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D. will outline the company's operations and growth strategy, aiming to bolster investor confidence in future developments.
- Financial Results: CFO Dennis McGrath will discuss PAVmed's first quarter 2026 financial results during the call, expected to provide key financial metrics to assess the company's market performance and financial health.
- Webcast Availability: The conference call will be available via webcast on the company's investor relations section, allowing investors to dial in through specified numbers, ensuring broad dissemination and transparency of information.
- Replay Accessibility: Following the call, a replay will be available for 30 days on the investor relations section of the company's website, facilitating access for investors who could not participate live, thereby enhancing communication efficiency between the company and its investors.
See More
PAVmed to Host Business Update Conference Call
- Conference Call Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and future growth potential.
- Webcast Availability: The webcast will be available on the investor relations section of the company's website, allowing global investors to participate in real-time and access the latest information, enhancing transparency and engagement.
- Replay Service: A replay of the call will be available for 30 days on the company's website, ensuring that investors who cannot attend live can still access important information, further improving communication efficiency between the company and its investors.
See More
PAVmed Set to Announce Q1 Earnings on May 15
- Earnings Announcement Date: PAVmed (PAVM) is scheduled to announce its Q1 earnings on May 15 after market close, with a consensus EPS estimate of -$0.69, reflecting a staggering 885.7% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations Decline: The anticipated revenue for Q1 is $0.07 million, representing a 12.5% year-over-year decrease, which highlights the company's struggles in revenue growth and may impact investor confidence and future financing capabilities.
- Historical Performance Review: Over the past two years, PAVmed has beaten EPS estimates 63% of the time and revenue estimates 50% of the time; however, the current expectations indicate a notable downturn, potentially affecting market perceptions of its future performance.
- Estimate Revision Status: In the last three months, there has been one upward revision and no downward revisions to EPS estimates, suggesting fluctuations in analyst confidence regarding the company's future performance, which may reflect broader concerns about its profitability.
See More
PAVmed Q1 2026 Earnings Call Insights
- Capital Structure Optimization: PAVmed has completed its restructuring, resulting in a clean capital structure consisting solely of common stock and term debt, which positions the company well to execute its high-growth, diversified life sciences mission.
- Medical Device Portfolio Relaunch: Under the leadership of Joe Virgilio, PAVmed is relaunching its medical device portfolio, including PortIO and endoscopic imaging technology licensed from Duke University, which is expected to drive the introduction of commercial assets and enhance market competitiveness.
- Improved Financial Position: As of March 31, PAVmed reported cash of $6.5 million, with an anticipated $30 million from warrant exercises, which will further bolster the company's liquidity and investment capacity.
- Profitability Challenges: Despite a GAAP net loss of $1.1 million in Q1, the adjusted loss per share was only $0.04 after excluding preferred dividends, indicating the company's efforts in cost control and operational optimization.
See More
PAVmed Q1 Earnings Miss Expectations
- Disappointing Earnings: PAVmed reported a Q1 non-GAAP EPS of -$1.17, missing expectations by $0.48, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company's revenue for Q1 was only $0.02 million, a sharp drop from $8,000 year-over-year, failing to meet the expected $0.08 million, reflecting weak market demand and insufficient sales strategies.
- Improved Cash Position: As of March 31, 2026, PAVmed had cash and cash equivalents of $6.5 million, a significant increase from $1.5 million as of December 31, 2025, indicating better cash management that may support future operations.
- Uncertain Future Outlook: Despite the improved cash position, ongoing losses and declining revenue may raise investor concerns about the company's growth potential, impacting its market performance and ability to secure financing.
See More
PAVmed Reports Business Expansion and Financial Update
- Financial Structure Optimization: PAVmed has simplified its capital structure and strengthened its balance sheet, enabling the company to focus on executing its core businesses and evaluate asset acquisition opportunities aligned with its long-term growth strategy, thereby laying a foundation for future expansion.
- Veris Health Progress: Veris Health continues to expand its commercial engagement with OSU-The James while advancing the FDA submission process for its implantable physiological monitor, which will enhance the company's market position in personalized cancer care.
- Lucid Diagnostics Momentum: Lucid Diagnostics has made significant progress in the commercialization of EsoGuard and strengthened its balance sheet ahead of upcoming Medicare coverage, which will support the company's future revenue growth.
- Medical Device Portfolio Relaunch: Under Joseph Virgilio's leadership, PAVmed is actively advancing its relaunched medical device portfolio while evaluating additional acquisition opportunities to enhance its market competitiveness and drive technological innovation.
See More
PAVmed to Host Business Update Conference Call
- Conference Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D. will outline the company's operations and growth strategy, aiming to bolster investor confidence in future developments.
- Financial Results: CFO Dennis McGrath will discuss PAVmed's first quarter 2026 financial results during the call, expected to provide key financial metrics to assess the company's market performance and financial health.
- Webcast Availability: The conference call will be available via webcast on the company's investor relations section, allowing investors to dial in through specified numbers, ensuring broad dissemination and transparency of information.
- Replay Accessibility: Following the call, a replay will be available for 30 days on the investor relations section of the company's website, facilitating access for investors who could not participate live, thereby enhancing communication efficiency between the company and its investors.
See More
PAVmed to Host Business Update Conference Call
- Conference Call Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and future growth potential.
- Webcast Availability: The webcast will be available on the investor relations section of the company's website, allowing global investors to participate in real-time and access the latest information, enhancing transparency and engagement.
- Replay Service: A replay of the call will be available for 30 days on the company's website, ensuring that investors who cannot attend live can still access important information, further improving communication efficiency between the company and its investors.
See More
